Compare THW & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THW | RXST |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.0M | 524.6M |
| IPO Year | N/A | 2021 |
| Metric | THW | RXST |
|---|---|---|
| Price | $13.07 | $10.79 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.30 |
| AVG Volume (30 Days) | 149.9K | ★ 807.7K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $9.76 | $6.32 |
| 52 Week High | $14.89 | $37.13 |
| Indicator | THW | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 42.75 |
| Support Level | $12.34 | $10.46 |
| Resistance Level | $13.18 | $13.14 |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | 0.06 | -0.31 |
| Stochastic Oscillator | 87.14 | 11.78 |
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry. The company's investment portfolio comprises investments in different sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other areas. It also male into REIT Real Estate.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.